The platelet and plasma market is set to record considerable growth in coming years due to the increasing occurrence of chronic diseases across the globe. In modern day medical therapies, patients can receive either a pint of complete blood or just specific components present within the blood that are essential to treat particular conditions. This treatment approach, known as a blood component treatment, enables several patients to receive more benefit from a single pint of the donated whole blood.

Blood contains several different components, which includes platelets, red blood cells, plasma, and white blood cells. Today, the demand for platelet and plasma donations is increasing tremendously as they can address particular conditions more effectively.

In platelet donations, platelets are collected from the blood of a donor and then the remaining blood and the components in it are returned back to the donor. These platelets allows blood to clot, and are commonly given to people suffering from leukemia, to people undergoing chemotherapy, and to babies suffering from severe infections.

Similarly, the liquid part of the blood, known as plasma, is collected from the donor with the remaining components of the blood being returned back to the donor. Plasma also effectively helps blood to form clots, and is commonly used to treat people suffering from liver conditions, severe bacterial infections within the blood and burns.

The overall platelet and plasma market is divided into segments based on component, application, distribution channel, and regional landscape.

By component, the market is divided into platelets, and plasma. Among these, the plasma segment is expected to record around 2% CAGR through the forecast timeframe due to the rising usage of plasma in rare chronic diseases such as autoimmune diseases, hemophilia, hereditary angioedema and other infectious diseases.

In terms of application, the market is divided into thrombocytopenia, hemophilia, platelet function disorders, perioperative Indications, coagulation factor deficiencies, other platelet applications, hemorrhage, thrombotic thrombocytopenic purpura, other plasma applications, and liver disease.

Among these, the perioperative indications held around 15% market share in 2019 due to the significant blood loss during major invasive surgeries that is compensated by transfusing platelets in the patients.

Based on distribution channel, the industry is classified into hospitals, ambulatory surgical centers, and others. The ambulatory surgical centers is likely to witness around 2.5% CAGR over the projected timeframe, due to the increasing preference of people towards ambulatory surgeries owing to the quality treatment at affordable prices.

Regionally, the LATAM market held a market value of over $460 million in 2019, owing to the growing incidence of hemophilia, autoimmune disorder, as well as other infectious diseases.